<DOC>
	<DOCNO>NCT02228590</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy , tolerability safety single treatment APL-130277 16 patient Parkinson 's Disease ( PD )</brief_summary>
	<brief_title>A Study Examine APL-130277 Patients With Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Apomorphine</mesh_term>
	<criteria>1 . Male female ≥18 year age . 2 . Clinical diagnosis Idiopathic PD 3 . Receiving stable dos Ldopa +/ adjunctive PD therapy least 4 week study participation . 4 . At least one OFF episode per day total daily OFF time &gt; 2 hour duration . 5 . Experience predictable OFF episodes morning awaken prior receive morning dose levodopa . 6 . Stage I III Hoehn Yahr scale `` ON '' state . 7 . If female childbearing potential , must agree use one follow method birth control : 8 . Willing able comply schedule visit , treatment plan , laboratory test , studyrelated procedure complete study . 9 . Able understand consent form , provide write informed consent . 1 . Atypical secondary parkinsonism 2 . Changes Ldopa PD drug dose regimen 4 week screen visit . 3 . Past treatment form apomorphine within 30 day Dosing Day 1 ( patient stop apomorphine reason lack efficacy OR tolerability issue may consider trial ) . 4 . Female pregnant lactating . 5 . Contraindications APOKYN hypersensitive apomorphine hydrochloride ingredient APOKYN ( notably sodium metabisulfite ) , Tigan® . 6 . Participation clinical trial within 14 day screen visit . 7 . Receipt investigational ( i.e. , unapproved ) medication within 30 day screen visit . 8 . Currently take , likely need take time course study 9 . Currently take dopamine antagonist deplete drug exclude anticholinergic and/or antihistamine anticholinergic effect . 10 . Drug alcohol dependency past 6 month . 11 . Clinically significant orthostatic hypotension . 12 . Malignant melanoma history previously treat malignant melanoma within 5 year . 13 . Clinically significant medical surgical laboratory abnormality judgment investigator . 14 . Psychiatric disorder , include limited dementia disorder , opinion Investigator require ongoing treatment would make study participation unsafe make treatment compliance difficult . 15 . Dementia preclude provide informed consent . 16 . Potential lack compliance followup judgment investigator . 17 . Any condition , current therapy , prior therapy ( within 30 day screen visit ) , , opinion Investigator , would make subject unsuitable study . 18 . Previous neurosurgery PD . 19 . Donation blood plasma 30 day prior dose . 20 . Presence canker mouth sore .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Parkinson 's Disease</keyword>
</DOC>